Introduction In biologic therapy, dose modification in carefully selected patients when
psoriasis is in remission could reduce treatment costs and the risks associated with drug …

Dose reduction of biologics for psoriasis could contribute to lower drug exposure. This study
evaluated a one-step, tightly controlled, biologic dose reduction strategy in a prospective …

Introduction: Biologic medications increase dramatically the burden of a chronic and high
prevalent disease like psoriasis. The objective of the study was to quantify the use of dose …

Introduction Despite the large routine use of biologic drugs in psoriasis treatment, the
majority of studies do not take into consideration dose‐adjustment practice in 'real …

Dose reduction of biologics for psoriasis could contribute to more efficient use of these
expensive medicines. Evidence on opinions of patients with psoriasis regarding dose …

Introduction Dose escalation and reduction of biologic treatments are frequent in clinical
practice. The aim of this systematic review is to summarise evidence on dose adjustment of …

Introduction In the event of failure of maintenance therapy with biologic agents for moderate
to severe plaque psoriasis, the possible approaches are to switch to another agent or …

Background Psoriasis is an immune-mediated chronic inflammatory skin disorder for which
several targeted biologic therapies became available in the last 10 years. Data from patients …

Background/objectives Tightly-controlled dose reduction was possible during 1 year in
psoriasis patients on adalimumab, etanercept or ustekinumab with low disease activity …

Background Treatment modifications, including dose escalations, dose reductions, switches,
discontinuations and restarts of biologics may be necessary in the management of psoriasis …